[
  {
    "symbol": "LLY",
    "publishedDate": "2025-01-30 11:06:53",
    "publisher": "Zacks Investment Research",
    "title": "Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-lly-earnings-expected-to-grow-what-to-20250130.jpg",
    "site": "zacks.com",
    "text": "Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://www.zacks.com/stock/news/2406742/eli-lilly-lly-earnings-expected-to-grow-what-to-know-ahead-of-next-week-s-release?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_9-2406742",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-01-30T11:06:53-05:00",
    "date_et": "2025-01-30"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-01-31 04:30:00",
    "publisher": "The Motley Fool",
    "title": "Billionaire Philippe Laffont Just Sold Top Artificial Intelligence Stocks Nvidia and AMD and Piled Into 2 Players Dominating Another High-Growth Billion-Dollar Industry",
    "image": "https://images.financialmodelingprep.com/news/billionaire-philippe-laffont-just-sold-top-artificial-intelligence-stocks-20250131.jpg",
    "site": "fool.com",
    "text": "As founder of Coatue Management, Philippe Laffont oversees $26.9 billion invested in more than 80 stocks, and though he buys players across many sectors, one in particular stands out. The billionaire is known for his investments in innovative companies, and he's generally found them in the area of technology.",
    "url": "https://www.fool.com/investing/2025/01/31/billionaire-philippe-laffont-just-sold-top-artific/",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-01-31T04:30:00-05:00",
    "date_et": "2025-01-31"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-01-31 13:52:00",
    "publisher": "GlobeNewsWire",
    "title": "FDA Approval of Eli Lilly's Omvoh for Crohn's Disease Adds a New Option, but Uptake May be Hampered by US Gastroenterologists' Brand Preferences Among the IL-23 Class, According to Spherix Global Insights",
    "image": "https://images.financialmodelingprep.com/news/fda-approval-of-eli-lillys-omvoh-for-crohns-disease-20250131.jpg",
    "site": "globenewswire.com",
    "text": "Despite greater physician pre-approval familiarity with Omvoh compared to J&J Innovative Medicine's Tremfya, gastroenterologists favor Tremfya over Omvoh for Crohn's disease Despite greater physician pre-approval familiarity with Omvoh compared to J&J Innovative Medicine's Tremfya, gastroenterologists favor Tremfya over Omvoh for Crohn's disease",
    "url": "https://www.globenewswire.com/news-release/2025/01/31/3018975/0/en/FDA-Approval-of-Eli-Lilly-s-Omvoh-for-Crohn-s-Disease-Adds-a-New-Option-but-Uptake-May-be-Hampered-by-US-Gastroenterologists-Brand-Preferences-Among-the-IL-23-Class-According-to-Sp.html",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-01-31T13:52:00-05:00",
    "date_et": "2025-01-31"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-01-31 19:03:43",
    "publisher": "CNBC",
    "title": "Jim Cramer's week ahead: Earnings from Amazon, Alphabet, Eli Lilly, Palantir",
    "image": "https://images.financialmodelingprep.com/news/jim-cramers-week-ahead-earnings-from-amazon-alphabet-eli-20250131.jpg",
    "site": "cnbc.com",
    "text": "CNBC's Jim Cramer on Friday walked investors through an earnings-heavy week, highlighting reports from Amazon, Alphabet, Eli Lilly and Palantir, as well as a key inflation metric from the Labor Department. \"When you get a week that's packed with important earnings reports and the monthly employment report plus the tariff news, you're usually better off sitting on your hands,\" he said.",
    "url": "https://www.cnbc.com/2025/01/31/jim-cramers-week-ahead-earnings-from-amazon-alphabet-eli-lilly-palantir.html",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-01-31T19:03:43-05:00",
    "date_et": "2025-01-31"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-01 08:45:00",
    "publisher": "The Motley Fool",
    "title": "3 Unstoppable Stocks You Can Buy and Hold for the Rest of Your Life",
    "image": "https://images.financialmodelingprep.com/news/3-unstoppable-stocks-you-can-buy-and-hold-for-20250201.jpg",
    "site": "fool.com",
    "text": "If you want stocks that you can buy and hold for not only years, but potentially the rest of your life, it's important to consider businesses that have massive growth opportunities. These are the types of companies that generate significant profits, are leaders within their respective industries, and are likely to remain dominant for years -- potentially decades.",
    "url": "https://www.fool.com/investing/2025/02/01/3-unstoppable-stocks-you-can-buy-and-hold/",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-01T08:45:00-05:00",
    "date_et": "2025-02-01"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-02 04:38:00",
    "publisher": "The Motley Fool",
    "title": "Got $1,000? 2 Top Growth Stocks to Buy Right Now",
    "image": "https://images.financialmodelingprep.com/news/got-1000-2-top-growth-stocks-to-buy-right-20250202.jpg",
    "site": "fool.com",
    "text": "Being a long-term investor isn't always easy, as you'll inevitably encounter downturns as well as the thriving bull periods that occur in a cyclical market. However, this is a far better alternative to attempting to time the market, a strategy that rarely works (and even when it does, rarely works consistently).",
    "url": "https://www.fool.com/investing/2025/02/02/got-1000-2-top-growth-stocks-to-buy-this-week/",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-02T04:38:00-05:00",
    "date_et": "2025-02-02"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-02 05:45:40",
    "publisher": "Investopedia",
    "title": "What To Expect in the Markets This Week",
    "image": "https://images.financialmodelingprep.com/news/what-to-expect-in-the-markets-this-week-20250202.jpg",
    "site": "investopedia.com",
    "text": "Earnings from tech, media, and pharmaceutical firms could be in the spotlight this week, with Google parent Alphabet (GOOG, GOOGL) and Amazon (AMZN) set to report, along with Disney (DIS) and weight-loss drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY).",
    "url": "https://www.investopedia.com/what-to-expect-in-the-markets-this-week-8783286",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-02T05:45:40-05:00",
    "date_et": "2025-02-02"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-02 08:05:00",
    "publisher": "The Motley Fool",
    "title": "With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?",
    "image": "https://images.financialmodelingprep.com/news/with-zepbound-not-matching-expectations-should-investors-give-up-20250202.jpg",
    "site": "fool.com",
    "text": "Over the past six months, Eli Lilly (LLY -1.48%) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the pharmaceutical giant is one of the undisputed leaders in the exciting market for weight loss drugs.",
    "url": "https://www.fool.com/investing/2025/02/02/with-zepbound-not-matching-expectations-should-inv/",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-02T08:05:00-05:00",
    "date_et": "2025-02-02"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-03 09:23:09",
    "publisher": "Zacks Investment Research",
    "title": "Eli Lilly Stock Before Q4 Earnings: To Buy or Not to Buy?",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-stock-before-q4-earnings-to-buy-or-20250203.jpg",
    "site": "zacks.com",
    "text": "Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.",
    "url": "https://www.zacks.com/stock/news/2408086/eli-lilly-stock-before-q4-earnings-to-buy-or-not-to-buy?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2408086",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-03T09:23:09-05:00",
    "date_et": "2025-02-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-03 09:30:00",
    "publisher": "The Motley Fool",
    "title": "3 Magnificent Stocks to Buy and Hold Forever",
    "image": "https://images.financialmodelingprep.com/news/3-magnificent-stocks-to-buy-and-hold-forever-20250203.jpg",
    "site": "fool.com",
    "text": "Some people are fair-weather friends; others are lifelong. It's a similar story with stocks.",
    "url": "https://www.fool.com/investing/2025/02/03/3-magnificent-stocks-to-buy-and-hold-forever/",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-03T09:30:00-05:00",
    "date_et": "2025-02-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-03 10:20:58",
    "publisher": "Zacks Investment Research",
    "title": "Curious about Lilly (LLY) Q4 Performance? Explore Wall Street Estimates for Key Metrics",
    "image": "https://images.financialmodelingprep.com/news/curious-about-lilly-lly-q4-performance-explore-wall-street-20250203.jpg",
    "site": "zacks.com",
    "text": "Evaluate the expected performance of Lilly (LLY) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
    "url": "https://www.zacks.com/stock/news/2408220/curious-about-lilly-lly-q4-performance-explore-wall-street-estimates-for-key-metrics?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm_preview-2408220",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-03T10:20:58-05:00",
    "date_et": "2025-02-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-03 12:20:35",
    "publisher": "Zacks Investment Research",
    "title": "Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts?",
    "image": "https://images.financialmodelingprep.com/news/will-these-5-big-drug-stocks-surpass-q4-earnings-20250203.jpg",
    "site": "zacks.com",
    "text": "Let's look at five pharma and drug companies, MRK PFE, LLY, AMGN and BMY, which are scheduled to release their fourth-quarter 2024 results later this week.",
    "url": "https://www.zacks.com/stock/news/2408529/will-these-5-big-drug-stocks-surpass-q4-earnings-forecasts?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_preview_esp-2408529",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-03T12:20:35-05:00",
    "date_et": "2025-02-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-03 13:40:46",
    "publisher": "Investopedia",
    "title": "What Analysts Think of Eli Lilly Stock Ahead of Earnings",
    "image": "https://images.financialmodelingprep.com/news/what-analysts-think-of-eli-lilly-stock-ahead-of-20250203.jpg",
    "site": "investopedia.com",
    "text": "Eli Lilly (LLY) is set to report fourth-quarter earnings before the bell Thursday, with analysts expecting rising sales and profit in the first full quarter since the company's weight-loss drugs were declared no longer in shortage.",
    "url": "https://www.investopedia.com/what-analysts-think-of-eli-lilly-stock-ahead-of-earnings-q4-fy-2024-preview-8784718",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-03T13:40:46-05:00",
    "date_et": "2025-02-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-04 17:37:54",
    "publisher": "Benzinga",
    "title": "What Thursday's Earnings Mean for This Pharma Giant",
    "image": "https://images.financialmodelingprep.com/news/what-thursdays-earnings-mean-for-this-pharma-giant-20250204.jpg",
    "site": "benzinga.com",
    "text": "Tomorrow, Eli Lilly (LLY), the world's largest drug company, reports earnings before the market opens. The options market is already predicting some major moves.",
    "url": "https://www.benzinga.com/trading-ideas/25/02/43482721/what-thursdays-earnings-mean-for-this-pharma-giant",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-04T17:37:54-05:00",
    "date_et": "2025-02-04"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-04 21:50:58",
    "publisher": "Investopedia",
    "title": "What Analysts Think of Eli Lilly Stock Ahead of Earnings",
    "image": "https://images.financialmodelingprep.com/news/what-analysts-think-of-eli-lilly-stock-ahead-of-20250204.jpg",
    "site": "investopedia.com",
    "text": "Eli Lilly (LLY) is set to report fourth-quarter earnings before the bell Thursday, with analysts expecting rising sales and profit in the first full quarter since the company's weight-loss drugs were declared no longer in shortage.",
    "url": "https://www.investopedia.com/what-analysts-think-of-eli-lilly-stock-ahead-of-earnings-q4-fy-2024-preview-update-8784718",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-04T21:50:58-05:00",
    "date_et": "2025-02-04"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-05 06:03:40",
    "publisher": "Reuters",
    "title": "Lilly needs a plan to spur weight-loss drug sales, investors say",
    "image": "https://images.financialmodelingprep.com/news/lilly-needs-a-plan-to-spur-weightloss-drug-sales-20250205.jpg",
    "site": "reuters.com",
    "text": "Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month forecast lower-than-expected fourth-quarter revenues for the drug.",
    "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-needs-plan-spur-weight-loss-drug-sales-investors-say-2025-02-05/",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-05T06:03:40-05:00",
    "date_et": "2025-02-05"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-05 10:00:55",
    "publisher": "CNBC International TV",
    "title": "Novo Nordisk CEO says firm's obesity pill could launch before Eli Lilly",
    "image": "https://images.financialmodelingprep.com/news/novo-nordisk-ceo-says-firms-obesity-pill-could-launch-20250205.jpg",
    "site": "youtube.com",
    "text": "Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral weight loss candidate.",
    "url": "https://www.youtube.com/watch?v=gvm1Wi4LuYI",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-05T10:00:55-05:00",
    "date_et": "2025-02-05"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-05 15:10:32",
    "publisher": "Benzinga",
    "title": "Eli Lilly Bulls Take Charge Ahead Of Q4 — Can It Reach $1000?",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-bulls-take-charge-ahead-of-q4-can-20250205.jpg",
    "site": "benzinga.com",
    "text": "Eli Lilly And Co LLY will be reporting its fourth-quarter earnings on Thursday. Wall Street expects $4.94 in EPS and $13.66 billion in revenues as the company reports before market hours.",
    "url": "https://www.benzinga.com/general/health-care/25/02/43507636/eli-lilly-bulls-charge-q4-earnings-1000-price-sight",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-05T15:10:32-05:00",
    "date_et": "2025-02-05"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 03:03:18",
    "publisher": "Benzinga",
    "title": "Eli Lilly Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-gears-up-for-q4-print-here-are-20250206.jpg",
    "site": "benzinga.com",
    "text": "Eli Lilly and Company LLY will release its fourth-quarter financial results, before the opening bell, on Thursday, Feb. 6, 2025.",
    "url": "https://www.benzinga.com/25/02/43520381/eli-lilly-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T03:03:18-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 06:45:00",
    "publisher": "PRNewsWire",
    "title": "Lilly reports full Q4 2024 financial results and provides 2025 guidance",
    "image": "https://images.financialmodelingprep.com/news/lilly-reports-full-q4-2024-financial-results-and-provides-20250206.jpg",
    "site": "prnewswire.com",
    "text": "Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023.",
    "url": "https://www.prnewswire.com/news-releases/lilly-reports-full-q4-2024-financial-results-and-provides-2025-guidance-302369432.html",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T06:45:00-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 06:50:53",
    "publisher": "Reuters",
    "title": "Eli Lilly forecasts 2025 profit largely above estimates on launch of weight-loss drug in new markets",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-forecasts-2025-profit-largely-above-estimates-on-20250206.jpg",
    "site": "reuters.com",
    "text": "Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular diabetes and weight-loss treatments in new markets.",
    "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-forecasts-2025-profit-largely-above-estimates-launch-weight-loss-drug-2025-02-06/",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T06:50:53-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 07:00:14",
    "publisher": "CNBC",
    "title": "Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-posts-mixed-quarter-even-as-demand-for-20250206.jpg",
    "site": "cnbc.com",
    "text": "Eli Lilly reported mixed results for the fourth quarter as sales of its blockbuster weight loss and diabetes drugs soared but saw lower realized prices. Demand in the U.S. has far outpaced supply for Eli Lilly's incretin drugs, such as Zepbound and Mounjaro, over the last year.",
    "url": "https://www.cnbc.com/2025/02/06/eli-lilly-lly-earnings-q4-2024.html",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T07:00:14-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 07:01:00",
    "publisher": "Barrons",
    "title": "Eli Lilly Stock Rises After Earnings Beat",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-stock-rises-after-earnings-beat-20250206.jpg",
    "site": "barrons.com",
    "text": "Fourth-quarter adjusted earnings of $5.32 a share beat analysts' estimates of $5.01.",
    "url": "https://www.barrons.com/articles/eli-lilly-stock-earnings-84d8e783",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T07:01:00-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 07:23:03",
    "publisher": "CNBC Television",
    "title": "Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-posts-mixed-quarter-even-as-demand-for-weight-20250206.jpg",
    "site": "youtube.com",
    "text": "CNBC's Angelica Peebles joins 'Squawk Box' to report on the company's quarterly earnings results.",
    "url": "https://www.youtube.com/watch?v=pbPwX437uq0",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T07:23:03-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 07:36:03",
    "publisher": "Investopedia",
    "title": "Eli Lilly Adjusted Profit Tops Estimates as Weight-Loss Drug Sales Fall Short",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-adjusted-profit-tops-estimates-as-weightloss-drug-20250206.jpg",
    "site": "investopedia.com",
    "text": "Eli Lilly (LLY) reported mostly worse-than-expected fourth-quarter results Thursday, but the drugmaker's adjusted profit came in above estimates.",
    "url": "https://www.investopedia.com/eli-lilly-q4-fy2024-earnings-mounjaro-zepbound-8786181",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T07:36:03-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 07:47:41",
    "publisher": "CNBC",
    "title": "Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-to-release-latestage-data-on-nextgeneration-weight-20250206.jpg",
    "site": "cnbc.com",
    "text": "Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, which is a few months earlier than expected.  The company expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.",
    "url": "https://www.cnbc.com/2025/02/06/eli-lilly-to-release-weight-loss-drug-retatrutide-data-in-2025.html",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T07:47:41-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 07:50:00",
    "publisher": "Market Watch",
    "title": "Lilly says Mounjaro and Zepbound contributed to big revenue boost",
    "image": "https://images.financialmodelingprep.com/news/lilly-says-mounjaro-and-zepbound-contributed-to-big-revenue-20250206.jpg",
    "site": "marketwatch.com",
    "text": "Lilly's CEO says that the company has “tremendous momentum” entering 2025.",
    "url": "https://www.marketwatch.com/story/lilly-issues-2025-profit-view-as-it-steers-for-revenue-boost-db5235eb",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T07:50:00-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 07:59:59",
    "publisher": "Benzinga",
    "title": "Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-q4-earnings-strong-demand-for-mounjaro-but-20250206.jpg",
    "site": "benzinga.com",
    "text": "On Thursday, Eli Lilly and Co LLY stock is trading higher after the company released better-than-expected fourth-quarter earnings and provided 2025 guidance.",
    "url": "https://www.benzinga.com/general/biotech/25/02/43525518/eli-lilly-q4-earnings-strong-demand-for-mounjaro-but-prices-dip-forecasts-over-30-jump-in-2025-sa",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T07:59:59-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 08:29:06",
    "publisher": "CNBC International TV",
    "title": "Novo, Lilly still leaders in obesity drug development: Barclays",
    "image": "https://images.financialmodelingprep.com/news/novo-lilly-still-leaders-in-obesity-drug-development-barclays-20250206.jpg",
    "site": "youtube.com",
    "text": "Emily Field, head of European pharmaceuticals research at Barclays, weighs in on rising competition in the global obesity drug market.",
    "url": "https://www.youtube.com/watch?v=zlr0IiwfiEE",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T08:29:06-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 08:56:21",
    "publisher": "Zacks Investment Research",
    "title": "Eli Lilly (LLY) Q4 Earnings and Revenues Top Estimates",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-lly-q4-earnings-and-revenues-top-estimates-20250206.jpg",
    "site": "zacks.com",
    "text": "Eli Lilly (LLY) came out with quarterly earnings of $5.32 per share, beating the Zacks Consensus Estimate of $5.03 per share. This compares to earnings of $2.49 per share a year ago.",
    "url": "https://www.zacks.com/stock/news/2410795/eli-lilly-lly-q4-earnings-and-revenues-top-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2410795",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T08:56:21-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 09:59:06",
    "publisher": "Proactive Investors",
    "title": "Eli Lilly Q4 earnings beat as weight loss drug sales miss estimates",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-q4-earnings-beat-as-weight-loss-drug-20250206.jpg",
    "site": "proactiveinvestors.com",
    "text": "Eli Lilly and Co (NYSE:LLY) reported mixed results for the fourth quarter, with earnings outpacing estimates as revenue from its weight loss drugs Mounjaro and Zepbound fell short.    Revenue surged 45% year-over-year to $13.53 billion, slightly below the $15.37 billion expected by Wall Street analysts.",
    "url": "https://www.proactiveinvestors.com/companies/news/1065827",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T09:59:06-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 10:20:00",
    "publisher": "Schwab Network",
    "title": "LLY Gains on Weight Loss Drugs, F Tariff Fears, HON Split",
    "image": "https://images.financialmodelingprep.com/news/lly-gains-on-weight-loss-drugs-f-tariff-fears-20250206.jpg",
    "site": "youtube.com",
    "text": "Eli Lilly (LLY) shares ran higher following its earnings report with its weight loss drugs in focus. Ford Motor Co. (F) hit a 52-week low with tariffs from President Trump posing questions around the company's outlook.",
    "url": "https://www.youtube.com/watch?v=46VE9c5as8k",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T10:20:00-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 11:29:18",
    "publisher": "The Motley Fool",
    "title": "Why Eli Lilly Stock Popped on Thursday",
    "image": "https://images.financialmodelingprep.com/news/why-eli-lilly-stock-popped-on-thursday-20250206.jpg",
    "site": "fool.com",
    "text": "Eli Lilly (LLY 4.07%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in this morning's Q4 earnings report.",
    "url": "https://www.fool.com/investing/2025/02/06/why-eli-lilly-stock-popped-on-thursday/",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T11:29:18-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 11:50:17",
    "publisher": "Zacks Investment Research",
    "title": "Weekly Jobless Claims Exceed Expectations",
    "image": "https://images.financialmodelingprep.com/news/weekly-jobless-claims-exceed-expectations-20250206.jpg",
    "site": "zacks.com",
    "text": "Weekly Jobless Claims Exceed Expectations.",
    "url": "https://www.zacks.com/stock/news/2411323/weekly-jobless-claims-exceed-expectations?cid=CS-STOCKNEWSAPI-FT-economic_highlights-2411323",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T11:50:17-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 11:50:24",
    "publisher": "Zacks Investment Research",
    "title": "LLY's Q4 Earnings Beat, Mounjaro, Zepbound Sales Fall Shy of Estimates",
    "image": "https://images.financialmodelingprep.com/news/llys-q4-earnings-beat-mounjaro-zepbound-sales-fall-shy-20250206.jpg",
    "site": "zacks.com",
    "text": "Eli Lilly beats fourth-quarter estimates for earnings and sales. Mounjaro and Zepbound sales miss estimates.",
    "url": "https://www.zacks.com/stock/news/2411322/lly-s-q4-earnings-beat-mounjaro-zepbound-sales-fall-shy-of-estimates?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2411322",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T11:50:24-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 12:01:09",
    "publisher": "Zacks Investment Research",
    "title": "Compared to Estimates, Lilly (LLY) Q4 Earnings: A Look at Key Metrics",
    "image": "https://images.financialmodelingprep.com/news/compared-to-estimates-lilly-lly-q4-earnings-a-look-20250206.jpg",
    "site": "zacks.com",
    "text": "The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
    "url": "https://www.zacks.com/stock/news/2411348/compared-to-estimates-lilly-lly-q4-earnings-a-look-at-key-metrics?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm-2411348",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T12:01:09-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 14:23:06",
    "publisher": "Seeking Alpha",
    "title": "Eli Lilly and Company (LLY) Q4 2024 Earnings Call Transcript",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-and-company-lly-q4-2024-earnings-call-20250206.jpg",
    "site": "seekingalpha.com",
    "text": "Eli Lilly and Company (NYSE:LLY ) Q4 2024 Results Conference Call February 6, 2025 10:00 AM ET Company Participants Mike Czapar - Senior Vice President of Investor Relations David Ricks - Chair and CEO Lucas Montarce - Chief Financial Officer Dr. Dan Skovronsky - Chief Scientific Officer & President of Lilly Immunology Patrik Jonsson - President of Lilly Cardiometabolic Health & Lilly USA Dave Hyman - Chief Medical Officer Anne White - President of Lilly Neuroscience Jake Van Naarden - President of Lilly Oncology Ilya Yuffa - President of Lilly International Marc Kemen - Investor Relations Wes Taul - Investor Relations Wai Wong - Investor Relations Conference Call Participants Tim Anderson - Bank of America Terence Flynn - Morgan Stanley Courtney Breen - Bernstein Chris Schott - JPMorgan Geoff Meacham - Citibank Colleen Garvey - Guggenheim Securities Conor MacKay - BMO Capital Markets Umer Raffat - Evercore Steve Scala - TD Cowen Mohit Bansal - Wells Fargo Dave Risinger - Leerink Partners Akash Tewari - Jefferies Alexandria Hammond - Wolfe Research Chris Shibutani - Goldman Sachs James Shin - Deutsche Bank Trung Huynh - UBS Nicole Germino - Truist Securities Operator Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q4 2024 Earnings Call. At this time all participants are in a listen-only mode.",
    "url": "https://seekingalpha.com/article/4755724-eli-lilly-and-company-lly-q4-2024-earnings-call-transcript",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T14:23:06-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 15:37:51",
    "publisher": "Seeking Alpha",
    "title": "Eli Lilly Q4 Earnings: Now The Magical $1 Trillion Dollar Market Cap Is In Sight",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-q4-earnings-now-the-magical-1-trillion-20250206.jpg",
    "site": "seekingalpha.com",
    "text": "Eli Lilly and Company's Q4 and full-year earnings showcased impressive growth, driven by tirzepatide's success, leading to a 45% revenue increase in Q4 and 32% for the year. Tirzepatide, marketed as Mounjaro for Type 2 Diabetes and Zepbound for Obesity, has significantly outperformed competitors, contributing to over 37% of Lilly's revenues. Lilly's diverse portfolio, including cardiometabolic, oncology, and immunology divisions, also showed strong growth, with significant investments in manufacturing to address supply concerns.",
    "url": "https://seekingalpha.com/article/4755736-eli-lilly-q4-earnings-now-the-magical-1-trillion-dollar-market-cap-is-in-sight",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T15:37:51-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-06 18:25:11",
    "publisher": "CNBC Television",
    "title": "Eli Lilly climbs after earnings, top analyst talks what's next for pharma giant",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-climbs-after-earnings-top-analyst-talks-whats-20250206.jpg",
    "site": "youtube.com",
    "text": "David Risinger, Leerink Partners, joins 'Fast Money' to talk Eli Lilly earnings.",
    "url": "https://www.youtube.com/watch?v=Be2UCvRZEWY",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-06T18:25:11-05:00",
    "date_et": "2025-02-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-07 06:45:00",
    "publisher": "PRNewsWire",
    "title": "Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years",
    "image": "https://images.financialmodelingprep.com/news/most-patients-on-lillys-omvoh-mirikizumabmrkz-for-crohns-disease-20250207.jpg",
    "site": "prnewswire.com",
    "text": "More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of patients who achieved endoscopic response at one year sustained it at two years Omvoh is the first IL-23p19 antagonist to demonstrate multi-year, sustained efficacy and safety for both Crohn's disease and ulcerative colitis INDIANAPOLIS , Feb. 7, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two years of continuous treatment with Omvoh® (mirikizumab-mrkz) achieved long-term clinical and endoscopic outcomes, including those (43.8%) with previous biologic failure. Data from this study will be presented at the Crohn's and Colitis Congress (CCC), being held from February 6-8, 2025 in San Francisco.1 Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation.2,3 \"Many people living with Crohn's disease have tried available therapies without success or have experienced a loss of efficacy with their treatment,\" said Edward Barnes, M.D.",
    "url": "https://www.prnewswire.com/news-releases/most-patients-on-lillys-omvoh-mirikizumab-mrkz-for-crohns-disease-achieved-sustained-clinical-remission-and-endoscopic-response-at-two-years-302370878.html",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-07T06:45:00-05:00",
    "date_et": "2025-02-07"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-07 09:43:03",
    "publisher": "Forbes",
    "title": "Buy, Sell, Or Hold LLY Stock At $870?",
    "image": "https://images.financialmodelingprep.com/news/buy-sell-or-hold-lly-stock-at-870-20250207.jpg",
    "site": "forbes.com",
    "text": "Eli Lilly (NYSE: LLY) fourth-quarter performance exceeded the street expectations, with the company delivering adjusted earnings of $5.32 per share versus the projected $4.95. Revenue came in at $13.5 billion, slightly below the consensus estimate of $13.6 billion.",
    "url": "https://www.forbes.com/sites/greatspeculations/2025/02/07/buy-sell-or-hold-lly-stock-at-870/",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-07T09:43:03-05:00",
    "date_et": "2025-02-07"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-07 10:18:44",
    "publisher": "Seeking Alpha",
    "title": "23 Upcoming Dividend Increases, Including 2 Kings",
    "image": "https://images.financialmodelingprep.com/news/23-upcoming-dividend-increases-including-2-kings-20250207.jpg",
    "site": "seekingalpha.com",
    "text": "Excited to announce dividend hikes for 23 companies, including dividend kings SJW Group and California Water Service Group, with 5% and 7.1% increases. Companies with consistent dividend growth indicate financial health, attracting investors and boosting stock prices, leading to long-term wealth accumulation. Investment strategy focuses on stocks with rising dividends and outperforming benchmarks, using data from U.S. Dividend Champions and NASDAQ.",
    "url": "https://seekingalpha.com/article/4756074-23-upcoming-dividend-increases-including-2-kings",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-07T10:18:44-05:00",
    "date_et": "2025-02-07"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-09 09:10:00",
    "publisher": "The Motley Fool",
    "title": "2 Growth Stocks to Buy Hand Over Fist in February",
    "image": "https://images.financialmodelingprep.com/news/2-growth-stocks-to-buy-hand-over-fist-in-20250209.jpg",
    "site": "fool.com",
    "text": "Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in other industries -- even in healthcare, a sector some investors might consider boring.",
    "url": "https://www.fool.com/investing/2025/02/09/2-growth-stocks-to-buy-hand-over-fist-in-february/",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-09T09:10:00-05:00",
    "date_et": "2025-02-09"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-10 08:35:14",
    "publisher": "MarketBeat",
    "title": "These Stocks Missed on Earnings, But Will Rebound Next Quarter",
    "image": "https://images.financialmodelingprep.com/news/these-stocks-missed-on-earnings-but-will-rebound-next-20250210.jpg",
    "site": "marketbeat.com",
    "text": "MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.",
    "url": "https://www.marketbeat.com/stock-ideas/these-stocks-missed-on-earnings-but-will-rebound-next-quarter/",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-10T08:35:14-05:00",
    "date_et": "2025-02-10"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-10 10:06:16",
    "publisher": "Zacks Investment Research",
    "title": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-and-company-lly-is-a-trending-stock-20250210.jpg",
    "site": "zacks.com",
    "text": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://www.zacks.com/stock/news/2412584/eli-lilly-and-company-lly-is-a-trending-stock-facts-to-know-before-betting-on-it?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2412584",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-10T10:06:16-05:00",
    "date_et": "2025-02-10"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-10 10:14:35",
    "publisher": "24/7 Wall Street",
    "title": "My 3 Top Picks for Stocks That Could Double Over the Next 3 Years",
    "image": "https://images.financialmodelingprep.com/news/my-3-top-picks-for-stocks-that-could-double-over-20250210.jpg",
    "site": "247wallst.com",
    "text": "Finding stocks with the potential to double in just three years is no easy feat, even in this bull market.",
    "url": "https://247wallst.com/investing/2025/02/10/my-3-top-picks-for-stocks-that-could-double-over-the-next-3-years/",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-10T10:14:35-05:00",
    "date_et": "2025-02-10"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-12 07:00:00",
    "publisher": "Business Wire",
    "title": "Kenai Therapeutics Establishes Research Facility at Lilly Gateway Labs",
    "image": "https://images.financialmodelingprep.com/news/kenai-therapeutics-establishes-research-facility-at-lilly-gateway-labs-20250212.jpg",
    "site": "businesswire.com",
    "text": "SAN DIEGO--(BUSINESS WIRE)--Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-shelf neuron replacement therapies for neurological conditions, today announced the establishment of the Company's research and laboratory facilities at Lilly Gateway Labs (Gateway Labs) in San Diego, which is operated in partnership with Alexandria Real Estate Equities, Inc. Kenai was selected to join the Gateway Labs c.",
    "url": "https://www.businesswire.com/news/home/20250212088159/en/Kenai-Therapeutics-Establishes-Research-Facility-at-Lilly-Gateway-Labs/",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-12T07:00:00-05:00",
    "date_et": "2025-02-12"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-13 08:00:19",
    "publisher": "MarketBeat",
    "title": "Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial",
    "image": "https://images.financialmodelingprep.com/news/will-eli-lilly-stock-keep-climbing-q2-trial-results-20250213.jpg",
    "site": "marketbeat.com",
    "text": "Eli Lilly and Company NYSE: LLY is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the stock market and healthcare system. Shares have performed well in 2025, with a total return of 12% as of the Feb. 11 close.",
    "url": "https://www.marketbeat.com/originals/will-eli-lilly-stock-keep-climbing-q2-trial-results-are-crucial/",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-13T08:00:19-05:00",
    "date_et": "2025-02-13"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-13 08:51:12",
    "publisher": "Zacks Investment Research",
    "title": "LLY Rises More Than 4% in a Week: How to Play the Stock",
    "image": "https://images.financialmodelingprep.com/news/lly-rises-more-than-4-in-a-week-how-20250213.jpg",
    "site": "zacks.com",
    "text": "Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.",
    "url": "https://www.zacks.com/stock/news/2415141/lly-rises-more-than-4-in-a-week-how-to-play-the-stock?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2415141",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-13T08:51:12-05:00",
    "date_et": "2025-02-13"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-13 13:39:26",
    "publisher": "CNBC Television",
    "title": "Calls of the Day: Live Nation, Eli Lilly, AT&T, Adobe and Astera Labs",
    "image": "https://images.financialmodelingprep.com/news/calls-of-the-day-live-nation-eli-lilly-att-20250213.jpg",
    "site": "youtube.com",
    "text": "The Investment Committee discuss the latest Calls of the Day.",
    "url": "https://www.youtube.com/watch?v=IiKNqHZESlA",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-13T13:39:26-05:00",
    "date_et": "2025-02-13"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-15 06:48:00",
    "publisher": "Invezz",
    "title": "Top 5 growth stocks to watch in 2025 as market momentum builds",
    "image": "https://images.financialmodelingprep.com/news/top-5-growth-stocks-to-watch-in-2025-as-20250215.jpg",
    "site": "invezz.com",
    "text": "While concerns about a potential US recession persist, growth stocks have continued to outperform value stocks in 2024. Investors remain optimistic that the Federal Reserve's expected interest rate cuts will further support high-growth companies.",
    "url": "https://invezz.com/news/2025/02/15/top-5-growth-stocks-to-watch-in-2025-as-market-momentum-builds/",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-15T06:48:00-05:00",
    "date_et": "2025-02-15"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-15 07:30:00",
    "publisher": "The Motley Fool",
    "title": "Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake",
    "image": "https://images.financialmodelingprep.com/news/think-eli-lillys-stock-is-expensive-heres-why-selling-20250215.jpg",
    "site": "fool.com",
    "text": "Investors should never ignore valuations when picking stocks. The price a stock trades at can drastically impact your overall returns.",
    "url": "https://www.fool.com/investing/2025/02/15/think-eli-lillys-stock-is-expensive-heres-why-sell/",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-15T07:30:00-05:00",
    "date_et": "2025-02-15"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-17 04:32:00",
    "publisher": "The Motley Fool",
    "title": "3 Stocks That Could Trounce the Market in 2025",
    "image": "https://images.financialmodelingprep.com/news/3-stocks-that-could-trounce-the-market-in-2025-20250217.jpg",
    "site": "fool.com",
    "text": "If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch.",
    "url": "https://www.fool.com/investing/2025/02/17/3-stocks-that-could-trounce-the-market-in-2025/",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-17T04:32:00-05:00",
    "date_et": "2025-02-17"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-18 10:00:00",
    "publisher": "PRNewsWire",
    "title": "Lilly to participate in TD Cowen's 45th Annual Health Care Conference",
    "image": "https://images.financialmodelingprep.com/news/lilly-to-participate-in-td-cowens-45th-annual-health-20250218.jpg",
    "site": "prnewswire.com",
    "text": "INDIANAPOLIS , Feb. 18, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Jake Van Naarden, executive vice president and president, Lilly Oncology, will take part in a fireside chat at 1:50 p.m.",
    "url": "https://www.prnewswire.com/news-releases/lilly-to-participate-in-td-cowens-45th-annual-health-care-conference-302378432.html",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-18T10:00:00-05:00",
    "date_et": "2025-02-18"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-19 09:22:00",
    "publisher": "The Motley Fool",
    "title": "Digging Into What Hershey and Eli Lilly Told Investors",
    "image": "https://images.financialmodelingprep.com/news/digging-into-what-hershey-and-eli-lilly-told-investors-20250219.jpg",
    "site": "fool.com",
    "text": "In this podcast, Motley Fool analyst Bill Barker and host Ricky Mulvey discuss:",
    "url": "https://www.fool.com/investing/2025/02/19/digging-into-what-hershey-and-eli-lilly-told-inves/",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-19T09:22:00-05:00",
    "date_et": "2025-02-19"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-20 08:48:01",
    "publisher": "CNBC",
    "title": "From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs",
    "image": "https://images.financialmodelingprep.com/news/from-pills-to-new-uses-heres-what-eli-lillys-20250220.jpg",
    "site": "cnbc.com",
    "text": "Eli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy. The development of pills and more potent drugs are two areas where Lilly is focusing.",
    "url": "https://www.cnbc.com/2025/02/20/eli-lilly-dan-skovronsky-discusses-weight-loss-drugs.html",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-20T08:48:01-05:00",
    "date_et": "2025-02-20"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-20 09:08:04",
    "publisher": "CNBC Television",
    "title": "Lilly's Chief Scientific Officer has big plans for the next generation of weight loss drugs",
    "image": "https://images.financialmodelingprep.com/news/lillys-chief-scientific-officer-has-big-plans-for-the-next-20250220.jpg",
    "site": "youtube.com",
    "text": "Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in obesity.",
    "url": "https://www.youtube.com/watch?v=P9k7kXmuzII",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-20T09:08:04-05:00",
    "date_et": "2025-02-20"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-20 09:12:52",
    "publisher": "CNBC Television",
    "title": "Lilly's Chief Scientific Officer: 'We have an obligation to go after big problems'",
    "image": "https://images.financialmodelingprep.com/news/lillys-chief-scientific-officer-we-have-an-obligation-to-go-20250220.jpg",
    "site": "youtube.com",
    "text": "Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in obesity.",
    "url": "https://www.youtube.com/watch?v=hMiMV2-JqaA",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-20T09:12:52-05:00",
    "date_et": "2025-02-20"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-20 10:15:33",
    "publisher": "Zacks Investment Research",
    "title": "Don't Overlook Lilly (LLY) International Revenue Trends While Assessing the Stock",
    "image": "https://images.financialmodelingprep.com/news/dont-overlook-lilly-lly-international-revenue-trends-while-assessing-20250220.jpg",
    "site": "zacks.com",
    "text": "Review Lilly's (LLY) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.",
    "url": "https://www.zacks.com/stock/news/2418526/don-t-overlook-lilly-lly-international-revenue-trends-while-assessing-the-stock?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm_international_revenues-2418526",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-20T10:15:33-05:00",
    "date_et": "2025-02-20"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2025-02-20 12:50:15",
    "publisher": "Reuters",
    "title": "Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-bets-big-on-weightloss-pill-with-550-20250220.jpg",
    "site": "reuters.com",
    "text": "Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in \"pre-launch inventory\" in its financial statements, a filing showed on Wednesday.",
    "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-bets-big-weight-loss-pill-with-550-million-inventory-stockpile-2025-02-20/",
    "ticker": "LLY",
    "event_date": "2025-02-06",
    "window_start": "2025-01-30",
    "window_end": "2025-02-20",
    "publishedDateET": "2025-02-20T12:50:15-05:00",
    "date_et": "2025-02-20"
  }
]